EP0868199A1 - Particle compositions - Google Patents
Particle compositionsInfo
- Publication number
- EP0868199A1 EP0868199A1 EP96943114A EP96943114A EP0868199A1 EP 0868199 A1 EP0868199 A1 EP 0868199A1 EP 96943114 A EP96943114 A EP 96943114A EP 96943114 A EP96943114 A EP 96943114A EP 0868199 A1 EP0868199 A1 EP 0868199A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- particles
- composition according
- enzymes
- composition
- antimicrobially active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002245 particle Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 102000004190 Enzymes Human genes 0.000 claims abstract description 29
- 108090000790 Enzymes Proteins 0.000 claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 230000000813 microbial effect Effects 0.000 claims abstract description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 15
- 235000011073 invertase Nutrition 0.000 claims description 15
- 239000001573 invertase Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- 229920002873 Polyethylenimine Polymers 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 102000004316 Oxidoreductases Human genes 0.000 claims description 6
- 108090000854 Oxidoreductases Proteins 0.000 claims description 6
- 102000003992 Peroxidases Human genes 0.000 claims description 5
- 241000194023 Streptococcus sanguinis Species 0.000 claims description 4
- 208000002064 Dental Plaque Diseases 0.000 claims description 3
- 241000194019 Streptococcus mutans Species 0.000 claims description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 claims 1
- 229960001545 hydrotalcite Drugs 0.000 claims 1
- 229910001701 hydrotalcite Inorganic materials 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 25
- 235000019420 glucose oxidase Nutrition 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 108010015776 Glucose oxidase Proteins 0.000 description 10
- 239000004366 Glucose oxidase Substances 0.000 description 10
- 229940116332 glucose oxidase Drugs 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 244000005700 microbiome Species 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 108700020962 Peroxidase Proteins 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108010023244 Lactoperoxidase Proteins 0.000 description 3
- 102000045576 Lactoperoxidases Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000010954 inorganic particle Substances 0.000 description 3
- 229940057428 lactoperoxidase Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 108010035722 Chloride peroxidase Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 108010016350 vanadium chloroperoxidase Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
- C11D17/0034—Fixed on a solid conventional detergent ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/12—Water-insoluble compounds
- C11D3/124—Silicon containing, e.g. silica, silex, quartz or glass beads
- C11D3/1246—Silicates, e.g. diatomaceous earth
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Definitions
- the present invention relates to compositions for the delivery of antimicrobially active proteins to a microbial cell target site.
- EP-A-0566368 (Unilever) describes cosmetic compositions for the delivery of a cosmetically effective benefit agent to a target site on the skin and/or hair comprising particles including the benefit agent and having means to bind to an organic surface at the target location.
- Suitable particles disclosed are made of synthetic polymeric substances such as polycyanoacrylate or proteins such as albumin or gelatin.
- Preferred particles which are disclosed and exemplified are liposomes in which benefit agent is encapsulated.
- inorganic particles particularly biodegradable metal oxides or salts
- a cell binding component i.e. a targetting molecule for a particular cell type
- BE-A-844657 discloses porous inorganic particles, such as silica, coated with an aminated polysaccharide which reversibly bind various biologically active molecules. The particles can be used in chromatographic processes to purify such molecules.
- JP-A-63031538 A similar material is disclosed in JP-A-63031538 in which a cationic polymer such as polyethyleneimine is used as the coating. In this case the binding is said to be irreversible.
- antimicrobially active proteins adsorbed onto a positively charged inorganic porous carrier particle which is able to bind to a microbial cell target site, can efficiently be delivered to the target site with high affinity and specificity. Retention of the antimicrobially active proteins at the target site and prolonged action may thereby be achieved. Furthermore, by adsorbing the proteins onto the particle carrier, the need for chemical coupling reactions can be avoided, leading to a simple process of manufacture which can readily be scaled-up.
- the present invention provides a composition comprising positively charged porous inorganic carrier particles having one or more antimicrobially active proteins adsorbed thereon.
- the invention provides a method for delivering antimicrobially active proteins to microbial cell targets comprising applying to the targets a composition according to the first aspect, and thereby inhibit or kill the microbial cell.
- the invention provides a method for the production of a composition according to the first aspect comprising providing the porous inorganic carrier particles with a positive electric charge and adsorbing one or more antimicrobially active proteins on the porous inorganic carrier particle.
- Suitable porous inorganic particles for use according to the invention include silicas such as available from Crosfield, W-R Grace or Rhone Poulenc and hydrotalcites such as available commercially from Crosfield.
- the porous particles will conveniently have a pore size to suit the molecular size of the proteins.
- the mean pore size should preferably be such that sufficient pores greater that 20nm, more preferably greater than 50nm are present. Pore sizes are preferably less than 200nm, but it is technically possible to use larger pores. It will be appreciated that other porous inorganic materials having properties analogous to those of silica may suitably be employed.
- An advantage of using carrier materials having a porous structure is that they have a large internal surface area able to accommodate a large payload of benefit agent .
- Positively charged inorganic (e.g. silica) particles may be produced by physical adsorption of a positively charged ligand onto the surface of the negatively charged silica particle.
- Suitable positively charged ligands which may be employed include organic polymers such as polyethylene imine or polylysine and metal ions such as Al 3* and Mg 2+ .
- Porous hydrotalcites such as those commercially available from
- Crosfield under the trade name Macrosorb naturally contain aluminium and magnesium ions and therefore carry an innate positive charge.
- Such carrier particles are therefore particularly useful in the present invention as they do not need to be further derivatised with a particularly charged ligand prior to use.
- antimicrobially active proteins refers to proteins which are either antimicrobially active themselves such that they directly act on the microorganism in such a way as to kill it or hinder its growth or multiplication, or to proteins which react with other compounds present in the microorganism or its environment thereby directly or indirectly producing compounds which have any of the above mentioned activities.
- the antimicrobially active proteins to be adsorbed onto the carrier particles preferably include one or more enzymes which are antimicrobially active themselves or in combination with a suitable substrate produce antimicrobially active molecules.
- enzymes which are antimicrobially active themselves or in combination with a suitable substrate produce antimicrobially active molecules.
- oxidases can function as cytotoxic agents. Oxidases such as glucose oxidase and galactose oxidase generate hydrogen peroxidase which is cytotoxic. Peroxidases can use the hydrogen peroxide as a substrate to form hypohalite which is even more cytotoxic.
- peroxidases which may suitably be used in conjunction with these oxidases include horseradish peroxidase and lactoperoxidase. Other suitable peroxidases are chloroperoxidases . Both hydrogen peroxide and hypohalite are rapidly decomposed in vivo, but nevertheless active because they can effectively be delivered to the intended site of action by the present invention.
- compositions according to the invention may also include other enzymes which aid the antimicrobially active enzymes in their action e.g. by converting a substrate present near the microbial cell into a substrate which in turn can be used by the antimicrobially active enzymes, such other enzymes are preferably also absorbed on the carrier particles.
- other enzymes are preferably also absorbed on the carrier particles.
- An example of such other enzyme is invertase, as outlined below.
- compositions according to the invention may conveniently be used for the delivery of antimicrobial agents as oral care active agents.
- one application of the invention lies in the delivery of oral care active agents, particularly oxidative enzymes as discussed above against the microbial species in dental plaque.
- Suitable target microorganisms include Streptococcus mutans and S sanguis.
- the particles may carry some or all of the substrates for the enzymes or some or all of the enzyme substrates may be present at the target site. For example, where glucose oxidase is used and the intended target microorganism is in the mouth, dietary glucose may be relied upon as the enzyme substrate or the particles may incorporate glucose. Alternatively, the particles may incorporate invertase which converts sucrose to glucose.
- Other enzymes may alter the pH of the environment, e.g. the dental plague, to a level which is not or less suitable for the microorganism to grow.
- certain enzymes are capable of raising the pH to a level unsuitable for growth of microorganisms in the dental plaque; an example is urease which converts ureum to ammonia and carbon dioxide.
- the target is microorganisms present on general household surfaces.
- microorganisms include S . aureus, P . aeruginosa and E. coli .
- Suitable benefit agents for use in this application include enzymes such as horseradish peroxidase, lactoperoxidase or vanadium chloroperoxidase.
- compositions of the invention preferably include a vehicle to act as a diluant, dispersant or carrier for the particles so as to facilitate their application to and distribution at the site of application.
- vehicle to act as a diluant, dispersant or carrier for the particles so as to facilitate their application to and distribution at the site of application.
- vehicle will depend on the method and site of administration of the composition.
- the vehicle must be acceptable for topical application in the mouth.
- Conventional cosmetically acceptable vehicles are well known in the art and can include water or substances such as liquid or solid emollients, solvents, humectants, thickeners and powders .
- compositions according to the invention intended for oral use may conveniently be formulated as a mouthwash, toothpaste or lozenge.
- the compositions of the invention may be solid or semi-solid, for example sticks, creams or gels for use in conjunction with a suitable applicator.
- the proportion of antimicrobially active protein in the compositions according to the invention varies depending upon the intended application.
- the benefit agent provides from 0.01% to 10% by weight of the particles.
- the benefit agent provides from 0.005% to 1.5% by weight of the composition.
- compositions according to the invention will generally contain various other components known in the art, depending on the intended application.
- such components will include the usual polishing agents.
- Many compositions will also include some sort of surface active or detergent active component.
- Tooth pastes and other compositions for oral care will also generally contain a suitable flavour, particularly a mint or menthol-like flavour.
- the vials were rotated slowly for 4 hours at room temperature. Then the particles were separated by centrifugation (2,000 r.p.m for 5 minutes) . The amount of invertase remaining in the supernatant was determined spectrophotometrically after filtering through an 0.2 ⁇ m filter. This value was subtracted from the amount of enzyme that had been added to deduce the amount of enzyme that had been adsorbed onto the particles.
- the invertase sensitised particles were resuspended in a 1.5mls volume of lOmM tris containing 2mgs of glucose oxidase (equivalent to 32mgs per gram of particles) .
- the tubes were rotated overnight at room temperature.
- the double-enzyme sensitised particles were separated by centrifugation and the amount of glucose oxidase that had been adsorbed was determined as previously. Particles were washed with and then stored in lOmM tris, pH8.
- Macrosorb particles (CT 100) were successfully derivatised with both invertase and glucose oxidase.
- the ratio of invertase to glucose had been efficiently controlled by sensitising with different amounts of invertase and a fixed amount of glucose oxidase in a two-step reaction (see Figure 2) .
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Ceramic Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Detergent Compositions (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
A composition for delivering an antimicrobially active protein, such as an enzyme, to a microbial cell target comprising, optionally in a vehicle, positively charged porous inorganic carrier particles having one or more antimicrobially active proteins adsorbed thereon.
Description
PARTICLE COMPOSITIONS
The present invention relates to compositions for the delivery of antimicrobially active proteins to a microbial cell target site. In particular, it relates to compositions in which the proteins are adsorbed on to an inorganic porous carrier particle by means of which they are delivered to the target site.
It is known to deliver a combination of enzymes, one of which produces a substrate for the other, conjugated through covalent bonds to a synthetic polymer such as polyethylene i ine, to a target site by means of an antibody or antibody fragment able to bind to the target site. Such an approach is described, for example, in EP-A-0450800 and EP-A-0451972 (Unilever) where preparations of particular use for attacking oral microflora are disclosed. Chemical coupling of the enzymes involves the use of reagents which may be toxic and' it is necessary to take steps to ensure their removal in products intended for oral use.
EP-A-0566368 (Unilever) describes cosmetic compositions for the delivery of a cosmetically effective benefit agent to a target site on the skin and/or hair comprising particles including the benefit agent and having means to bind to an organic surface at the target location. Suitable particles disclosed are made of synthetic polymeric substances such as polycyanoacrylate or proteins such as albumin or gelatin. Preferred particles which are disclosed and exemplified are liposomes in which benefit agent is encapsulated.
It is known from O-A-93/05815 to target nucleic acids to cells by providing inorganic particles (particularly biodegradable metal oxides or salts) with a cell binding component, i.e. a targetting molecule for a particular cell type, and the nucleic acid.
BE-A-844657 discloses porous inorganic particles, such as silica, coated with an aminated polysaccharide which reversibly bind various biologically active molecules. The particles can be used in chromatografic processes to purify such molecules.
A similar material is disclosed in JP-A-63031538 in which a cationic polymer such as polyethyleneimine is used as the coating. In this case the binding is said to be irreversible.
It has now been found that antimicrobially active proteins, adsorbed onto a positively charged inorganic porous carrier particle which is able to bind to a microbial cell target site, can efficiently be delivered to the target site with high affinity and specificity. Retention of the antimicrobially active proteins at the target site and prolonged action may thereby be achieved. Furthermore, by adsorbing the proteins onto the particle carrier, the need for chemical coupling reactions can be avoided, leading to a simple process of manufacture which can readily be scaled-up.
According to a first aspect, the present invention provides a composition comprising positively charged porous inorganic carrier particles having one or more antimicrobially active proteins adsorbed thereon.
In a second aspect, the invention provides a method for delivering antimicrobially active proteins to microbial cell targets comprising applying to the targets a composition according to the first aspect, and thereby inhibit or kill the microbial cell.
In a further aspect, the invention provides a method for the production of a composition according to the first aspect comprising providing the porous inorganic carrier particles with a positive electric charge and adsorbing one or more antimicrobially active proteins on the porous inorganic
carrier particle.
Suitable porous inorganic particles for use according to the invention include silicas such as available from Crosfield, W-R Grace or Rhone Poulenc and hydrotalcites such as available commercially from Crosfield. The porous particles will conveniently have a pore size to suit the molecular size of the proteins. For example, if the protein is a large enzyme, the mean pore size should preferably be such that sufficient pores greater that 20nm, more preferably greater than 50nm are present. Pore sizes are preferably less than 200nm, but it is technically possible to use larger pores. It will be appreciated that other porous inorganic materials having properties analogous to those of silica may suitably be employed. An advantage of using carrier materials having a porous structure is that they have a large internal surface area able to accommodate a large payload of benefit agent .
Positively charged inorganic (e.g. silica) particles may be produced by physical adsorption of a positively charged ligand onto the surface of the negatively charged silica particle. Suitable positively charged ligands which may be employed include organic polymers such as polyethylene imine or polylysine and metal ions such as Al3* and Mg2+. Porous hydrotalcites, such as those commercially available from
Crosfield under the trade name Macrosorb, naturally contain aluminium and magnesium ions and therefore carry an innate positive charge. Such carrier particles are therefore particularly useful in the present invention as they do not need to be further derivatised with a particularly charged ligand prior to use.
For the purposes of this invention the phrase "antimicrobially active proteins" refers to proteins which are either antimicrobially active themselves such that they directly act on the microorganism in such a way as to kill it or hinder its growth or multiplication, or to proteins which
react with other compounds present in the microorganism or its environment thereby directly or indirectly producing compounds which have any of the above mentioned activities.
Thus, the antimicrobially active proteins to be adsorbed onto the carrier particles preferably include one or more enzymes which are antimicrobially active themselves or in combination with a suitable substrate produce antimicrobially active molecules. Examples are various oxidases and peroxidases, proteases, glycosidases, lipases etc. In particular, oxidases can function as cytotoxic agents. Oxidases such as glucose oxidase and galactose oxidase generate hydrogen peroxidase which is cytotoxic. Peroxidases can use the hydrogen peroxide as a substrate to form hypohalite which is even more cytotoxic. Commercially available peroxidases which may suitably be used in conjunction with these oxidases include horseradish peroxidase and lactoperoxidase. Other suitable peroxidases are chloroperoxidases . Both hydrogen peroxide and hypohalite are rapidly decomposed in vivo, but nevertheless active because they can effectively be delivered to the intended site of action by the present invention.
The compositions according to the invention may also include other enzymes which aid the antimicrobially active enzymes in their action e.g. by converting a substrate present near the microbial cell into a substrate which in turn can be used by the antimicrobially active enzymes, such other enzymes are preferably also absorbed on the carrier particles. An example of such other enzyme is invertase, as outlined below.
Compositions according to the invention may conveniently be used for the delivery of antimicrobial agents as oral care active agents. In particular, one application of the invention lies in the delivery of oral care active agents, particularly oxidative enzymes as discussed above against the microbial species in dental plaque. Suitable target microorganisms include Streptococcus mutans and S sanguis.
The particles may carry some or all of the substrates for the enzymes or some or all of the enzyme substrates may be present at the target site. For example, where glucose oxidase is used and the intended target microorganism is in the mouth, dietary glucose may be relied upon as the enzyme substrate or the particles may incorporate glucose. Alternatively, the particles may incorporate invertase which converts sucrose to glucose.
Other enzymes may alter the pH of the environment, e.g. the dental plague, to a level which is not or less suitable for the microorganism to grow. Thus, certain enzymes are capable of raising the pH to a level unsuitable for growth of microorganisms in the dental plaque; an example is urease which converts ureum to ammonia and carbon dioxide.
In a further preferred embodiment of the invention, the target is microorganisms present on general household surfaces. Examples of such microorganisms include S . aureus, P . aeruginosa and E. coli . Suitable benefit agents for use in this application include enzymes such as horseradish peroxidase, lactoperoxidase or vanadium chloroperoxidase.
It will be appreciated that the invention is not limited to the various applications described above.
The compositions of the invention preferably include a vehicle to act as a diluant, dispersant or carrier for the particles so as to facilitate their application to and distribution at the site of application. It will be appreciated that the choice of vehicle will depend on the method and site of administration of the composition. For any oral application, for example, the vehicle must be acceptable for topical application in the mouth. Conventional cosmetically acceptable vehicles are well known in the art and can include water or substances such as liquid or solid emollients, solvents, humectants, thickeners and
powders .
Where the composition is intended for oral (dental) application, the cosmetically acceptable vehicle will generally form from 10 to 99.9%, preferably form 50 to 99.9% by weight of the composition. Compositions according to the invention intended for oral use may conveniently be formulated as a mouthwash, toothpaste or lozenge. Alternatively, the compositions of the invention may be solid or semi-solid, for example sticks, creams or gels for use in conjunction with a suitable applicator.
The proportion of antimicrobially active protein in the compositions according to the invention varies depending upon the intended application. Typically the benefit agent provides from 0.01% to 10% by weight of the particles. Generally the benefit agent provides from 0.005% to 1.5% by weight of the composition.
The compositions according to the invention will generally contain various other components known in the art, depending on the intended application. In the case of tooth pastes such components will include the usual polishing agents. Many compositions will also include some sort of surface active or detergent active component. Tooth pastes and other compositions for oral care will also generally contain a suitable flavour, particularly a mint or menthol-like flavour.
EXAMPLES
The following examples are given by way of illustration.
I) r-erivatisation of silica with polyethyleneimine (PET)
Two samples of porous silica particles were obtained from Crosfield: SD1497 (= Gasil 23DP, particle size 5μm, mean pore diameter ca 22nm) and SD1498 (particle size 4μm, mean pore diameter ca 80nm, a wide pore silica prepared according to WO 94/11302) . Each sample was derivatised by rotating overnight in an 0.2% solution of polyethylene imine (PEI) (Sigma) at room temperature. Derivatised silica was separated by centrifugation and then washed three times in lOmM tris, pH8.
II) Adsorption of glucose oxidase enzyme onto particles
Six different particles were investigated: SD1497 and SD1498 derivatised with PEI, underivatised SD1497 and SD1498, Macrosorb CT100 (particle size 3.7μm, mean pore diameter 30nm) and Macrosorb CT2000M (particle size 4μm, mean pore diameter lOnm) . An 0.5 mis aliquot of a 12.5% slurry (total mass of particles = 62.5 mgs) of each of these particles was mixed with 4mgs of glucose oxidase enzyme made up in lOmM tris pH8. The total volume of the mixture was 2 mis. The mixture was gently rotated overnight at room temperature. Then the particles were separated by centrifugation. The amount of enzyme remaining in the supernatant was determined spectro-photometrically after filtering through an 0.2μm filter. This value was subtracted from the amount of enzyme that had been added to deduce the amount of enzyme that had been adsorbed onto the particles.
All the particles with positively charged surfaces bound glucose oxidase. SD1498 derivatised with PEI had the highest capacity (88mg of enzyme per gram of solid) . Neither of the underivatised silicas bound glucose oxidase (see Figure 1) .
III) Adsorption of invertase and glucose oxidase onto
Macrosorb particles
A 12.5% slurry of Macrosorb (CT 100) was made up in lOmM tris pH8. 0.5 mis aliquots of this slurry (total mass of particles = 62.5 mgs) were added to glass vials. Then invertase (Sigma) was added from a stock solution (5mg/ml in lOmM tris, pH8) . Different amounts of invertase were added to each vial: 0, O.lmg, 0.2mg, 0.5mg, 1.0 mg and 5.0 mg; equivalent to 0, 1.6mg, 3.2mg, 8mg, 16mgs and 80mgs per gram of particles. Each vial was made up to 1.5mls with lOmM tris pH8. The vials were rotated slowly for 4 hours at room temperature. Then the particles were separated by centrifugation (2,000 r.p.m for 5 minutes) . The amount of invertase remaining in the supernatant was determined spectrophotometrically after filtering through an 0.2μm filter. This value was subtracted from the amount of enzyme that had been added to deduce the amount of enzyme that had been adsorbed onto the particles.
The invertase sensitised particles were resuspended in a 1.5mls volume of lOmM tris containing 2mgs of glucose oxidase (equivalent to 32mgs per gram of particles) . The tubes were rotated overnight at room temperature. The double-enzyme sensitised particles were separated by centrifugation and the amount of glucose oxidase that had been adsorbed was determined as previously. Particles were washed with and then stored in lOmM tris, pH8.
Macrosorb particles (CT 100) were successfully derivatised with both invertase and glucose oxidase. The ratio of invertase to glucose had been efficiently controlled by sensitising with different amounts of invertase and a fixed amount of glucose oxidase in a two-step reaction (see Figure 2) .
IV) Kill of Streptococci sά-tll Macrosorb particles
derivatised with invertase and σlucose oxidase
An overnight broth culture of S. sanguis cells was washed in phosphate-buffered saline (PBS) pH7 by repeated centrifugation and finally resuspended in PBS pH6.5 such that the final reaction mixture (cells + particles + substrate) contained the original culture cell density. Enzyme-loaded Macrosorb samples obtained according to Example III were added, with thorough mixing, to the S . sanguis suspension, to a final concentrations of 0.5% solids and- finally enzyme substrate was added (9.6% sucrose, lOmM KI, lOug/ml lactoperoxidase) . Immediately following addition of substrate, a time zero sample was removed from the reaction mixture for viability measurement. Further samples were removed following 1, 5, 10, 20 and 30 minutes of incubation at 37°C. During incubation, settling of Macrosorb particles was prevented by periodic agitation. Samples were removed into quenching solution comprising 12 mg/ml cystein hydrochloride in PBS pH6.5 followed by enumeration of viable cells by the Miles, Misra and Irwin method (A A Miles, S S Misra and J 0 Irwin, Journal of Hygiene 1938 3_&, 737-48) .
In the presence of Macrosorb particles labelled with both invertase and glucose oxidase, together with the substrate system defined, loss of viability of suspended S . sanguis cells occurred rapidly: an 8log reduction in cell viability was observed in 5 to 10 minutes of substrate incubation (see Figure 3) . The particles given greatest invertase loading did not provide the most potent kill, indicating the desirability to balance the GOx: invertase loading ratio to achieve optimal potency.
Claims
1. A composition comprising positively charged porous inorganic carrier particles having one or more antimicrobially active proteins adsorbed thereon.
2. A composition according to claim 1 wherein the particles comprise silica or hydrotalcite.
3. A composition according to any one of claims 1 and 2 wherein the antimicrobially active proteins comprise one or more enzymes.
4. A composition according to claim 3 wherein the enzymes comprise an oxidase.
5. A composition according to claim 3 or 4 wherein the enzymes comprise a peroxidase.
6. A composition according to claims 3-5 wherein the enzymes also comprise an invertase.
7. A composition according to any one of claims 1-6 wherein the silica particles are treated with polyethylene imine.
8. A composition according to any one of claims 1 to 7 further comprising a vehicle.
9. A composition according to any one of claims 1 to 8 which is a composition for oral care.
10. A composition according to any one of claims 1 to 8 which is a composition for cleaning household surfaces.
11. A method for delivering an antimicrobially active protein to a microbial cell target comprising applying a composition according to any one of claims 1 to 8.
12. A method according to claim 11 wherein the microbial cell target is present in dental plaque.
13. A method according to claim 12 wherein the microbial cells are those of S. mutans or S. sanguis .
14. A method according to claim 11 wherein the microbial cell target is present on household surfaces.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96943114A EP0868199A1 (en) | 1995-12-21 | 1996-12-05 | Particle compositions |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95309346 | 1995-12-21 | ||
EP95309349 | 1995-12-21 | ||
EP95309349 | 1995-12-21 | ||
EP95309347 | 1995-12-21 | ||
EP95309347 | 1995-12-21 | ||
EP95309346 | 1995-12-21 | ||
PCT/EP1996/005601 WO1997023241A1 (en) | 1995-12-21 | 1996-12-05 | Particle compositions |
EP96943114A EP0868199A1 (en) | 1995-12-21 | 1996-12-05 | Particle compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0868199A1 true EP0868199A1 (en) | 1998-10-07 |
Family
ID=27236942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96943114A Withdrawn EP0868199A1 (en) | 1995-12-21 | 1996-12-05 | Particle compositions |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0868199A1 (en) |
JP (1) | JP2000503000A (en) |
AU (1) | AU1194697A (en) |
WO (1) | WO1997023241A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100359716B1 (en) * | 1998-09-11 | 2003-04-21 | (주)나노하이브리드 | Live-inorganic hybrid complexes capable of storing and transferring genes and methods of manufacturing the same |
GB9924334D0 (en) * | 1999-10-15 | 1999-12-15 | Secr Defence | Pharmaceutical products and methods of fabrication therefor |
IL150476A0 (en) * | 1999-12-30 | 2002-12-01 | Aventis Pharma Sa | Compositions comprising nucleic acids incorporated in bilaminar mineral particles |
FR2803206A1 (en) * | 1999-12-30 | 2001-07-06 | Aventis Pharma Sa | New composition, used in in vitro or ex vivo cellular transfection, comprises a nucleic acid and a mineral particle with an exchangeable layer structure |
DE10021165A1 (en) * | 2000-04-29 | 2001-11-08 | Henkel Kgaa | Active substance release system |
US9540631B1 (en) * | 2004-09-14 | 2017-01-10 | Peter T. Pugliese | Immobilized glucose oxidase for use in oral hygiene |
US20220169955A1 (en) * | 2019-02-04 | 2022-06-02 | Conopco Inc., D/B/A Unilever | Cleaning compositions |
WO2020239627A1 (en) * | 2019-05-28 | 2020-12-03 | Unilever Plc | Oral care composition |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU73094A1 (en) * | 1975-07-29 | 1977-03-24 | ||
JPS6331538A (en) * | 1986-07-25 | 1988-02-10 | Kensetsusho Doboku Kenkyu Shocho | Immobilizing carrier |
DE69024323T2 (en) * | 1989-10-27 | 1996-10-17 | Genencor Int | Antimicrobial method and formulation using Type II endoglycosidase and antimicrobial agent |
GB8928501D0 (en) * | 1989-12-18 | 1990-02-21 | Unilever Plc | Reagents |
AU642980B2 (en) * | 1990-03-21 | 1993-11-04 | Quest International B.V. | Ultilization of enzymes |
AU642979B2 (en) * | 1990-03-21 | 1993-11-04 | Quest International B.V. | Utilization and delivery of enzymes |
GB9119762D0 (en) * | 1991-09-16 | 1991-10-30 | Filler Aaron G | Particulate agents for nmt |
US5811382A (en) * | 1991-12-20 | 1998-09-22 | Novo Nordisk A/S | Detergent compositions |
JPH09504790A (en) * | 1993-11-01 | 1997-05-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Biochemically active substances for chemical catalysis and cell receptor activation |
-
1996
- 1996-12-05 JP JP09523269A patent/JP2000503000A/en active Pending
- 1996-12-05 WO PCT/EP1996/005601 patent/WO1997023241A1/en not_active Application Discontinuation
- 1996-12-05 EP EP96943114A patent/EP0868199A1/en not_active Withdrawn
- 1996-12-05 AU AU11946/97A patent/AU1194697A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9723241A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1997023241A1 (en) | 1997-07-03 |
AU1194697A (en) | 1997-07-17 |
JP2000503000A (en) | 2000-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goldberg et al. | Mechanism of enhancement of microbial cell hydrophobicity by cationic polymers | |
US4814098A (en) | Magnetic material-physiologically active substance conjugate | |
US5206156A (en) | Process for the preparation of a particulate antimicrobial product, antimicrobial product obtained and applications thereof | |
Beachey et al. | Bacterial adherence: the attachment of group A streptococci to mucosal surfaces | |
Prabhawathi et al. | Design of antimicrobial polycaprolactam nanocomposite by immobilizing subtilisin conjugated Au/Ag core-shell nanoparticles for biomedical applications | |
EP0158909A2 (en) | Immobilized enzymes, processes for preparing same and use thereof | |
JP4077126B2 (en) | Denatured protein, method for producing the same, and external preparation composition containing the denatured protein | |
CN108178780B (en) | Short peptide modified tannic acid nano antibacterial agent and preparation method thereof | |
Yilmaz et al. | Synthesis of taurine-Cu3 (PO4) 2 hybrid nanoflower and their peroxidase-mimic and antimicrobial properties | |
EP0868199A1 (en) | Particle compositions | |
Vına et al. | Stabilization of anti-leukemic enzyme L-asparaginase by immobilization on polysaccharide levan | |
US4138476A (en) | Plaque dispersing enzymes as oral therapeutic agents by molecular alteration | |
Strominger et al. | How penicillin kills bacteria: progress and problems | |
JPS63171678A (en) | Reformed solid material | |
JPH0584073A (en) | Use of enzyme | |
Morehouse et al. | Properties of rat renal phosphate-dependent glutaminase coupled to Sepharose. Evidence that dimerization is essential for activation | |
EP0824019A1 (en) | Enzyme containing oral compositions | |
JPS63168346A (en) | Improved solid material | |
JPH0441597B2 (en) | ||
Brkich et al. | Miramistin as an antimicrobial component in the innovative substance of Chitosan-Miramistin Complex (CMC) for the treatment of infected wounds of various genesis | |
JPH053275B2 (en) | ||
Rawyler et al. | Cyclodextrins: a new tool for the controlled lipid depletion of thylakoid membranes | |
Colonna et al. | Site-directed PEGylation as successful approach to improve the enzyme replacement in the case of prolidase | |
Pennington et al. | Silastic entrapment of glucose oxidase–peroxidase and acetylcholine esterase | |
CN114796270A (en) | Meyer sedge nano-silver, preparation and application thereof, nano-silver gel, preparation and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980608 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI NL SE |
|
17Q | First examination report despatched |
Effective date: 20010130 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010612 |